Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; none of the 17 sources its claims cite is checked for support yet.
Abstract
B-cell lines and primary PBMCs are notoriously hard to transfect, thus making genome editing, ectopic gene expression, or gene silencing experiments particularly tedious. Here we propose a novel efficient and reproducible protocol for electrotransfection of lymphoblastoid, B-cell lymphoma, leukemia cell lines, and B cells from PBMCs. The proposed protocol requires neither costly equipment nor expensive reagents; it can be used with small or large plasmids. Transfection and viability rates of about 79% and 58%, respectively, have been routinely achieved by optimizing the salt concentration in the electrotransfection medium and the amount of plasmid used. A validation of the protocol was obtained via the generation of a TP53-/- RPMI8866 lymphoblastoid cell line which should prove useful in future hematological and blood cancer studies.
Overview
CoChat Summary
TL;DR
The paper presents an optimized electrotransfection protocol for hard-to-transfect human B-cell lines and PBMCs, using salt concentration and plasmid amount adjustments to improve GFP expression and viability. It validates the protocol by generating TP53−/− RPMI8866 cells via CRISPR/Cas9 without viral vectors.
Key findings
- In RPMI8866 LCL, using 50 µg pCMV-GFP in 50% water/50% S-MEM with 1300 V/cm, eight 100 µs pulses at 1 Hz gave 79.2±4.6% transfection and 58.3±4.8% viability, compared with 55.3±2.3% and 68±3% using 10 µg under the same salt conditions.
- The protocol yielded transfection efficiency of 41–73% and viability of 20–55% in Priess and Remb1 LCLs, BL2 Burkitt lymphoma, and RS4;11 acute lymphoblastic leukemia cell lines.
- For PBMCs, a modified protocol (50% SHM, 4-mm cuvettes, 1500 V/cm, 24 pulses) gave 1.5±0.5% transfection and 30.4±1.9% viability at 24 h; among transfected/living cells, 83.7±3.0% were CD3+ T cells and 7.1±2.0% CD19+ B cells.
- Large Cas9-GFP plasmid (13.5 Kbp) gave lower transfection: 1.1±0.1% with 10 µg and 4.6±0.8% with 50 µg, with viability of 64.3±4.3% and 61.7±1.2%, respectively. The protocol generated TP53−/− RPMI8866 clones with PCR amplicons of 350 bp and 400 bp, no p53 mRNA/protein, and reduced p21 expression.
Methods
- Optimization in RPMI8866 LCL: cells were transferred to fresh medium 48 h before electrotransfection; 5×10⁵ cells were resuspended in 100 µL of S-MEM, water, and pCMV-GFP (3.5 Kbp) and electrotransfected with a Cliniporator and 1-mm cuvettes at 1300 V/cm, eight 100 µs pulses at 1 Hz. Efficiency and viability were measured 48 h later by flow cytometry (BD Accuri C6), with viability calculated relative to non-electrotransfected controls.
- Salt/plasmid variation: 10 µg pCMV-GFP was tested with different water/S-MEM ratios, and 50 µg was tested in 50% water/50% S-MEM; the protocol was applied to other B-cell lines and PBMCs. PBMCs were purified by Pancoll density gradient from healthy donors; modified conditions used 400 µL total volume, 50% SHM, 4-mm cuvettes, 1500 V/cm, 24 pulses, and analysis at 24 and 48 h.
- Genome editing: 8×10⁶ RPMI8866 cells were electrotransfected with 30 µg Cas9-GFP and 20 µg phU6 plasmids encoding two gRNAs (10 µg each) in 400 µL in 4-mm cuvettes; GFP+ cells were sorted 48 h later at one cell per well, and clones were screened by PCR for TP53 exons 2 and 11 and confirmed by qRT-PCR and Western blot for p53 and RT-qPCR for p21. Statistics used means ± SEM, at least two biological replicates, and one-way ANOVA with Bonferroni post-test.
Limitations
- The paper does not state a dedicated limitations section; no author-stated limitations are provided.
- Evident from the text: PBMC transfection remained low (1.5±0.5% at 24 h) with 30.4±1.9% viability, and the transfected/living population was mostly CD3+ T cells (83.7±3.0%) rather than CD19+ B cells (7.1±2.0%), indicating limited efficiency for primary B cells.
- Evident from the text: large plasmid (Cas9-GFP, 13.5 Kbp) transfection rates were much lower (1.1±0.1% with 10 µg; 4.6±0.8% with 50 µg) than small pCMV-GFP, and optimized conditions reduced viability (58.3±4.8% vs 68±3% with 10 µg).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 13 Not checked · 24 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We then sorted cells every seven days during four weeks to obtain a cell population containing 93% GFP-positive cells.”
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Applying the protocol thus established to other B-cell lines, namely the Priess and Remb1 LCLs, the BL2 Burkitt lymphoma line, and the RS4;11 acute lymphoblastic leukemia cell line, yielded similar results (transfection efficiency of 41 to 73%; viability rates of 20 to 55%) (Figure 1d).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The described protocol was also suitable for stable expression of the transgene (Supplementary Figure 2).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The electrotransfection efficiency and viability rates (Figure 1bc) did not prove significantly better than other protocols used in previous studies.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transfection and viability rates of about 79% and 58%, respectively, have been routinely achieved by optimizing the salt concentration in the electrotransfection medium and the amount of plasmid used.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
13 more claims
Create a free account to see all 37 claims and to verify the 15 references still open.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most microchannel-based systems use low-conductivity media to prevent electrolysis-induced bubbling; however, LCL electroporation requires a culture medium with electrolytes [35].”
From Gene electrotransfer with flow-through microchannel and lower alternating voltage generated induced pluripotent cells from human lymphoblastoid cell lines (2025) · cites this paper as [35]
In the citing paper
“While low conductivity buffers are commonly used in electroporation, including bulk-type methods, some studies have successfully employed buffers similar to cell culture media, such as Opti-MEM I [35,50–52].”
From Gene electrotransfer with flow-through microchannel and lower alternating voltage generated induced pluripotent cells from human lymphoblastoid cell lines (2025) · cites this paper as [35]
In the citing paper
“For example, a transfection efficiency of 79% with 58% viability (48 h after processing) has been reported for LCLs using a bulk-type electroporator and pCMV-GFP plasmid.”
From Gene electrotransfer with flow-through microchannel and lower alternating voltage generated induced pluripotent cells from human lymphoblastoid cell lines (2025) · cites this paper as [35]
In the citing paper
“The lower transfection efficiency in our system is likely due to the nature of LCLs, which are considered “hard-to-transfect cells” compared to other cell lines [35,54].”
From Gene electrotransfer with flow-through microchannel and lower alternating voltage generated induced pluripotent cells from human lymphoblastoid cell lines (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B-cells > Additional information
“The effective knock-out was confirmed by PCR of genomic DNA (b), western blotting (c) and RT-qPCR for p53 downstream target p21 (d) from one control and two KO lines.”
§ Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B-cells > Additional information
“(d) Analysis of p21 transcription in two control and two KO RPMI-8866 lines.”
Citations
Cites
Mammalian cell transfection: the present and the future
Kim, T. K., & Eberwine, J. H. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3821-6 · Cited by 678
Towards safe, non-viral therapeutic gene expression in humans
Glover, D. J., Lipps, H. J., & Jans, D. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1577 · Cited by 598
p21: a two-faced genome guardian.
Georgakilas, A. G., Martin, O. A., & Bonner, W. M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.001 · Cited by 489
Kreiss, P. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.19.3792 · Cited by 279
Comparative transfection of DNA into primary and transformed mammalian cells from different lineages
Maurisse, R., De Semir, D., Emamekhoo, H., Bedayat, B., Abdolmohammadi, A., Parsi, H., & Gruenert, D. C. (2010) · BMC Biotechnology · doi:10.1186/1472-6750-10-9 · Cited by 228
Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells
Rols, M. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.01.005 · Cited by 176
Overcoming the Specific Toxicity of Large Plasmids Electrotransfer in Primary Cells In Vitro
Lesueur, L. L., Mir, L. M., & André, F. M. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.4 · Cited by 118
Self-citationMeacham, J. M., Durvasula, K., Degertekin, F. L., & Fedorov, A. G. (2014) · SLAS Technology · doi:10.1177/2211068213494388 · Cited by 107
An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells
Chicaybam, L., Barcelos, C., Peixoto, B., Carneiro, M., Limia, C. E. G., Redondo, P., de Morais, C. C. P. D. L., Paraguassú-Braga, F. H., de Vasconcelos, Z. F. M., Barros, L. R. C., et al. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00099 · Cited by 100
Silve, A., Leray, I., Poignard, C., & Mir, L. M. (2016) · Scientific Reports · doi:10.1038/srep19957 · Cited by 87
Cited by
Transfection types, methods and strategies: a technical review
Chong, Z. X., Yeap, S. K., & Ho, W. Y. (2021) · PeerJ · doi:10.7717/peerj.11165 · Cited by 303
Factors That Affect the Formation of Chromosomal Translocations in Cells
Canoy, R. J., Shmakova, A., Karpukhina, A. A., Shepelev, M. V., Germini, D., & Vassetzky, Y. S. (2022) · Cancers · doi:10.3390/cancers14205110 · Cited by 29
Self-citationEpstein−Barr virus reactivation induces MYC‐IGH spatial proximity and t(8;14) in B cells
Sall, F. B., Shmakova, A., Karpukhina, A. A., Tsfasman, T., Lomov, N. A., Canoy, R. J., Boutboul, D., Oksenhendler, É., Touré, A. O., Lipinski, M., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28633 · Cited by 20
Self-citationShmakova, A., Hugot, C., Kozhevnikova, Y., Karpukhina, A. A., Tsimailo, I., Gérard, L., Boutboul, D., Oksenhendler, É., Szewczyk-Roszczenko, O. K., Roszczenko, P., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29423 · Cited by 17
Self-citationMicrofluidic Mechanoporation: Current Progress and Applications in Stem Cells
Wang, R., Wang, Z., Tong, L., Wang, R., Yao, S., Chen, D., & Hu, H. (2024) · Biosensors · doi:10.3390/bios14050256 · Cited by 16
Metadata
- Authors
- Canoy, R. J., André, F., Shmakova, A., Wiels, J., Lipinski, M., Vassetzky, Y., & Germini, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Vassetzky, Yegor
- Germini, Diego
- Venue
- Gene Therapy
- Published
- 2020-09-30
- Volume
- 30
- Issue
- 1-2
- Pages
- 167-171
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W3091057210
- Semantic Scholar
- 89c3a286700829ee01261ddbed8b271569f551ea
- Cited by
- 31
- References
- 19
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 9
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- ANRS INSERM
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- electrotransfection, human B cells, primary B cells, genome editing, ectopic expression, gene silencing, lymphoblastoid cell lines, B-cell lymphoma cell lines, leukemia cell lines, plasmid transfection, TP53 knockout
- MeSH terms
- Ectopic Gene Expression, Gene Editing, Cell Line, Humans, Plasmids, Transfection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells. https://app.cochat.ai/papers/10.1038/s41434-020-00194-x
- The paper
- Canoy, R. J., André, F., Shmakova, A., Wiels, J., Lipinski, M., Vassetzky, Y., & Germini, D. (2023). Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells. Gene Therapy. https://doi.org/10.1038/s41434-020-00194-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.